Clinical Trials Logo

Filter by:
NCT ID: NCT00110812 Completed - HIV Infections Clinical Trials

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

STALWART
Start date: September 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in HIV infected patients. The effects will be compared with a study group that receives no IL-2 or antiretroviral therapy. Study hypothesis: Intermittent aldesleukin, when given without antiretroviral therapy to patients with early HIV infection, will produce no change in HIV viral load and increases in CD4+ T lymphocyte counts comparable to aldesleukin administered with antiretrovirals.

NCT ID: NCT00110305 Completed - Clinical trials for Human Immunodeficiency Virus Type 1

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.

NCT ID: NCT00109408 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate 7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

NCT ID: NCT00108953 Completed - Clinical trials for Carcinoma, Hepatocellular

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT00108914 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Perennial Allergic Rhinitis Study In Pediatric Subjects

Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.

NCT ID: NCT00108758 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.

NCT ID: NCT00106808 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.

NCT ID: NCT00106691 Completed - Clinical trials for Prostatic Intraepithelial Neoplasia

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).

NCT ID: NCT00106574 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start date: April 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with traditional Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy in patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to current DMARD therapy. Patients will be randomized to receive tocilizumab 8mg/kg iv or placebo iv every 4 weeks, in conjunction with stable DMARD therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00106548 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start date: n/a
Phase: Phase 3
Study type: Interventional

This 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with methotrexate (MTX). in patients with moderate to severe active rheumatoid arthritis (RA) who currently have an inadequate response to MTX. Patients wil be randomized to receive tocilizumab 4mg/kg iv, tocilizumab 8mg/mg iv, or placebo iv, every 4 weeks; all patients will also receive methotrexate 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.